ADVENTRX Acquires SynthRx

Scott-Macon provides merger and acquisition services within their Chemicals Group.

April 2011


ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced the completion its acquisition of SynthRx, Inc. SynthRx’s lead product candidate is a novel, proprietary, rheologic and antithrombotic compound, poloxamer 188, that ADVENTRX will develop as ANX-188.

By adding ANX-188 to their pipeline, ADVENTRX will have another late-stage sickle cell asset with multiple development opportunities.


ADVENTRX Pharmaceuticals is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. ADVENTRX has built their product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for heart failure, a condition with a high unmet need for innovative treatment options.

About Scott Macon’s Chemical Industries Group and M&A Services

Our chemicals practice professionals serve with more than 30 years of experience, and possess significant chemicals investment banking experience from serving a wide range of clients in the industry. Scott-Macon’s Chemical transaction group includes corporate advisory and strategic advisory as well as capital market assignments in both the public and private markets.

In addition to the outright sale of a company or business unit, Scott-Macon’s professionals have experience in a wide range of shareholder and liquidity-driven transactions. Scott-Macon professionals have significant experience assisting clients in acquiring businesses, either as stand-alone acquisitions or for integration into existing client operations. Our clients have ranged from large global corporations looking to expand their existing operations to private equity funds seeking to build a new or existing portfolio investment.